Direct answer
The CA-125 test is a blood test that measures cancer antigen 125, a protein shed by many cells lining the abdomen, pelvis and chest. The CA-125 test is used mainly to monitor known ovarian cancer and to help assess an ovarian mass. The CA-125 test cannot diagnose ovarian cancer on its own.
Key takeaways
- The CA-125 test is a tumour marker, not a cancer diagnosis.
- Many non-cancer conditions raise CA-125, especially before menopause.
- A normal CA-125 does not exclude ovarian cancer, including some early-stage and some mucinous cancers.
- The CA-125 test is not recommended as a general screening test for women at average risk.
- Trends across several CA-125 results usually matter more than a single number.
At a glance
| Item | Detail |
|---|---|
| Sample | Blood drawn from an arm vein |
| Fasting | Not usually needed unless other tests require it |
| Time for blood draw | About 5 to 10 minutes, including paperwork and pressure over the site |
| Total visit time | Often 20 to 45 minutes, depending on queue at the collection centre |
| Main uses | Monitoring treated ovarian cancer, assessing a known pelvic or ovarian mass, tracking response and recurrence |
| Not suitable for | Routine screening in women at average risk |
| Reported as | Units per millilitre (U/mL) |
Also known as
- Cancer antigen 125
- CA 125 blood test, CA-125 tumour marker
- MUC16 (the gene and protein name)
- Commonly asked for in India as "ovary cancer marker test", "CA 125 serum test", "ovarian tumour marker"
What the CA-125 test is
CA-125 is a large protein (MUC16) produced by cells derived from the coelomic epithelium, the lining of the ovaries, fallopian tubes, uterus, peritoneum, pleura and pericardium. When these surfaces are irritated, inflamed or invaded by tumour, more CA-125 enters the bloodstream.
Because the source tissue is widespread, CA-125 is a marker of irritation of these linings rather than a marker specific to cancer. This single fact explains most of the confusion patients have about their result.
Laboratories report CA-125 in U/mL. Many laboratories use an upper reference limit around 35 U/mL, but the exact cut-off depends on the assay and the laboratory. Always read the result against the reference range printed on your own report, and do not compare values across different laboratories or assay platforms.
Why the CA-125 test is done
- Monitoring treated ovarian cancer: tracking response to chemotherapy or surgery, and watching for recurrence during follow-up.
- Assessing an ovarian or pelvic mass: combined with ultrasound findings and menopausal status in risk indices used by gynaecological oncologists.
- Supporting assessment of unexplained ascites or pleural effusion, alongside imaging and fluid analysis.
- Occasionally in suspected endometriosis, though CA-125 is neither sensitive nor specific enough to confirm or exclude it.
- Surveillance in high-risk women (for example, BRCA1/BRCA2 pathogenic variants or strong family history) in specialist genetics or gynaecological oncology clinics, usually alongside transvaginal ultrasound, and with the clear caveat that this strategy has not been shown to reduce deaths from ovarian cancer.
Who should get this test
- Women already diagnosed with epithelial ovarian, fallopian tube or primary peritoneal cancer, for monitoring.
- Women with an ovarian mass or complex cyst found on ultrasound, where a specialist needs help judging the risk of malignancy and deciding on referral.
- Women with unexplained abdominal distension, persistent bloating, early satiety, pelvic or abdominal pain, or urinary urgency lasting more than a few weeks, after a clinical assessment, not as a self-ordered test.
- Women under specialist surveillance because of an inherited cancer risk.
Who generally should not have it: women with no symptoms and no increased risk. In this group, CA-125 produces a high proportion of false alarms, leading to anxiety, repeat imaging and sometimes surgery that was never needed. Screening trials have not shown that CA-125-based screening lowers ovarian cancer deaths in the general population.
What the CA-125 test cannot detect or exclude
- It cannot diagnose cancer. Diagnosis requires imaging, surgical assessment and histopathology.
- A normal CA-125 does not exclude ovarian cancer. A substantial proportion of early-stage ovarian cancers have CA-125 within the reference range. Mucinous, clear cell and some borderline tumours often do not raise CA-125.
- It cannot tell cancer from benign disease. A raised value in a premenopausal woman is more often due to endometriosis, fibroids, infection or normal menstruation than to cancer.
- It cannot localise disease. CA-125 rises in liver cirrhosis, heart failure, tuberculous peritonitis, pancreatitis, pleural disease and after abdominal surgery.
- It cannot identify tumour type. Germ cell and sex-cord stromal ovarian tumours are assessed with different markers.
- It is not a substitute for cervical screening. CA-125 says nothing about cervical cancer; Pap smear and HPV testing do that.
A result described as "not raised" means CA-125 was not elevated in that sample at that time. That is not the same as disease being ruled out. If symptoms persist despite a normal result, go back to your doctor.
Related but different tests
| Test | What question it answers | How it differs from CA-125 |
|---|---|---|
| Transvaginal / pelvic ultrasound (USG) | Is there a mass? What does it look like, simple cyst, complex, solid, with blood flow? | Shows structure; CA-125 shows a blood protein. Neither replaces the other. In India, all ultrasound is performed under the PC-PNDT Act 1994 framework. |
| HE4 (human epididymis protein 4) | Adds specificity, as HE4 is less affected by endometriosis and fibroids | Used with CA-125 in the ROMA index; less affected by benign gynaecological conditions but can rise in kidney disease. |
| ROMA / RMI indices | What is the estimated risk that this mass is malignant? | Calculations combining CA-125 (with or without HE4), menopausal status and ultrasound score, not a standalone blood test. |
| CEA, CA 19-9 | Suggest gastrointestinal or mucinous origin | A CA-125 to CEA ratio is sometimes used when a mass may be a spread from bowel or stomach cancer. |
| AFP, beta-hCG, LDH, inhibin, AMH | Markers for germ cell and sex-cord stromal ovarian tumours | Relevant particularly in younger women; CA-125 is a marker for epithelial tumours. |
| CT or MRI pelvis | Extent of disease, spread, surgical planning | Structural staging information that CA-125 cannot provide. |
| Histopathology / biopsy | What is this tissue? | The only test that establishes a cancer diagnosis. |
How to prepare
- Fasting: not usually required for CA-125 alone. If your doctor has clubbed it with lipid or glucose tests, follow the fasting instruction for those.
- Timing in the menstrual cycle: CA-125 can rise during menstruation and in the early follicular phase. Where the result matters for a borderline decision, many clinicians prefer sampling outside the period. Tell the laboratory where you are in your cycle.
- Recent events to mention: pregnancy, recent delivery or miscarriage, recent abdominal or pelvic surgery, laparoscopy, recent pelvic infection, or a recent flare of endometriosis.
- Medicines and supplements: list everything, including AYUSH and herbal preparations. Do not stop any prescribed medicine for this test, speak to the prescriber first.
- High-dose biotin supplements can interfere with some immunoassays; mention if you take them.
- Follow-up testing: where possible, have serial CA-125 tests done at the same laboratory on the same assay, so the trend is meaningful.
Preparation rules, appointment timings and sample stability requirements differ between collection centres and laboratories. Your own unit's written instructions take precedence over any general guidance.
If you are pregnant
CA-125 is commonly raised in the first trimester and around delivery. The CA-125 test is not used to assess pregnancy and is rarely helpful for ovarian assessment in pregnancy without specialist input.
If you have liver, kidney or heart disease
Cirrhosis with ascites, nephrotic syndrome, chronic kidney disease and heart failure can all raise CA-125 without any gynaecological disease being present. Tell the requesting doctor about these conditions.
Children and adolescents
CA-125 is rarely useful in young girls. Ovarian tumours in this age group are more often germ cell tumours, assessed with AFP, beta-hCG and LDH.
Older adults after menopause
Benign causes of a raised CA-125 become less common after menopause, so an elevated value carries more weight, but it still requires imaging and specialist assessment before any conclusion.
What happens during the test and how long it takes
A phlebotomist cleans a spot on your arm, applies a tourniquet and draws a few millilitres of blood into a plain or gel tube. The needle is in the vein for well under a minute. The whole blood draw takes about five to ten minutes; total time at the centre is usually 20 to 45 minutes depending on the queue.
You can eat, drive and return to work straight away. Keep firm pressure on the puncture site for a couple of minutes to reduce bruising, and longer if you take blood thinners.
Reporting time depends on whether the laboratory runs the immunoassay in-house or sends samples to a reference laboratory. Ask your collection centre for their expected reporting time.
Understanding your CA-125 report
Your report will show a numerical CA-125 value in U/mL alongside the laboratory's own reference interval. Read these three points before you interpret anything.
- The number is a signal, not a verdict. Only the doctor who requested the CA-125 test, with your symptoms, examination and imaging in front of them, can interpret it.
- Context changes meaning completely. The same value can be unremarkable in a menstruating 28-year-old with endometriosis and important in a 62-year-old with a complex adnexal mass and ascites.
- Trend beats snapshot. In women being monitored after treatment, a rising trend across serial samples is more informative than any single reading. A rise on paper may still precede symptoms or scan changes, and treatment decisions are not made on the marker alone.
If your result is above the reference limit, expect your doctor to ask about symptoms, examine you, and usually arrange a pelvic ultrasound. Depending on findings, further imaging, additional markers such as HE4, or referral to a gynaecological oncologist may follow. A mildly raised value in a premenopausal woman is frequently repeated after some weeks to see whether it settles.
Results vary depending on individual clinical circumstances.
When CA-125 results can be misleading
Causes of a falsely raised or non-cancer elevation
- Menstruation and the early follicular phase
- Endometriosis and adenomyosis
- Uterine fibroids, ovarian cysts, ovarian torsion
- Pelvic inflammatory disease and other pelvic infections
- Pregnancy, especially the first trimester, and the postpartum period
- Recent abdominal or pelvic surgery, laparoscopy, or peritoneal dialysis
- Liver cirrhosis with ascites, heart failure, pancreatitis, pleural effusion
- Abdominal or pleural tuberculosis, a genuinely important cause in India, which can mimic advanced ovarian cancer on both scans and marker levels
- Non-ovarian cancers including endometrial, pancreatic, lung, breast and colorectal cancer
- Laboratory interference: heterophile antibodies, high-dose biotin, or haemolysed samples
Causes of a falsely low or falsely reassuring result
- Early-stage epithelial ovarian cancer that has not yet raised the marker
- Mucinous, clear cell and some borderline ovarian tumours, which often do not express CA-125
- Germ cell and sex-cord stromal tumours, which use different markers
- A very high antigen concentration overwhelming the assay (hook effect), uncommon, and laboratories dilute samples when suspected
- Changing laboratory or assay platform mid-follow-up, which can make a rising trend look flat
Risks and safety
Risks of the blood draw
Venepuncture risks are small: soreness, bruising, a small haematoma, brief light-headedness or fainting, and rarely local infection. Bruising is more likely if you take anticoagulants or antiplatelet medicines, mention this before the draw.
Risks of the information itself
The more significant risk with CA-125 is not the needle. It is over-interpretation. A borderline result in a woman at low risk can trigger repeated scans, anxiety and occasionally surgery that turns out to have been unnecessary. This is why the CA-125 test is best ordered for a defined clinical question rather than as part of a general health package.
Red flags
Emergency: go to hospital now
- Sudden severe one-sided pelvic or lower abdominal pain, with vomiting, possible ovarian torsion or cyst rupture
- Fainting, rapid pulse, cold clammy skin or severe abdominal pain with a distended abdomen
- High fever with severe pelvic pain and foul-smelling vaginal discharge
- Sudden breathlessness or chest pain
- Complete inability to pass stool or urine, with vomiting and a swollen abdomen
Same-day or urgent medical review
- Rapidly increasing abdominal swelling or clothes suddenly feeling tight at the waist
- New heavy or postmenopausal vaginal bleeding
- Persistent vomiting or inability to keep fluids down
- Fever with pelvic pain that is not improving
Book a routine appointment
- Bloating, early fullness after small meals, pelvic discomfort or urinary urgency persisting beyond two to three weeks
- A CA-125 result above the reference range on a report you have received
- Unexplained weight loss, fatigue or change in bowel habit
- Family history of ovarian, breast, uterine or colorectal cancer, to discuss whether genetic assessment is appropriate
Special situations
Premenopausal women
Benign causes dominate. A single mildly raised CA-125 in a menstruating woman usually prompts a repeat test and ultrasound rather than alarm.
Postmenopausal women
Benign gynaecological causes are fewer, so a raised CA-125 with an adnexal mass carries more weight and typically leads to prompt specialist referral.
Women with endometriosis
CA-125 is often raised, sometimes considerably, particularly with endometriomas. The CA-125 test cannot confirm endometriosis and is not used to monitor it routinely.
Women with BRCA variants or strong family history
Surveillance may include CA-125 with transvaginal ultrasound, but this has not been shown to reduce mortality. Risk-reducing surgery and genetic counselling are the substantive conversations here, and should happen in a specialist clinic.
Women with tuberculosis or chronic liver disease
Both can raise CA-125 markedly and produce ascites. Distinguishing abdominal tuberculosis from ovarian malignancy usually needs imaging, ascitic fluid analysis including adenosine deaminase and culture, and sometimes laparoscopic biopsy.
The CA-125 test in the Indian context
- Tuberculosis matters here. Abdominopelvic tuberculosis is relatively common in India and can produce ascites, omental thickening, pelvic masses and a high CA-125, a picture almost identical to advanced ovarian cancer. Tissue or fluid confirmation before any irreversible decision is essential.
- Health packages. CA-125 sometimes appears in "women's health" or "cancer marker" panels marketed directly to consumers. For women at average risk with no symptoms, this frequently creates false alarms rather than earlier diagnosis.
- Assay variability across labs. With patients often moving between hospital and neighbourhood laboratories, mixing assays during follow-up is a real problem. Stay with one laboratory for serial monitoring where you can.
- Late presentation. Ovarian cancer in India is frequently diagnosed at an advanced stage because early symptoms are vague. Persistent bloating and early satiety deserve a clinical assessment rather than a self-ordered blood test.
- Ultrasound regulation. Pelvic ultrasound, usually done alongside CA-125, is governed by the PC-PNDT Act 1994; registered centres will document the indication and will not disclose fetal sex.
- Data privacy. Laboratory reports and any online form you fill are personal health data protected under the Digital Personal Data Protection Act 2023.
Cost and insurance in India
CA-125 is a widely available immunoassay and is generally an inexpensive to moderately priced test at Indian laboratories, with wide variation between cities, standalone laboratories and hospital-based departments. Ask for the current charge at the point of booking.
What drives the price:
- City and whether the laboratory is hospital-attached or standalone
- Assay platform, and whether the sample is run in-house or referred out
- Urgency, stat processing usually costs more
- Whether the CA-125 test is bundled with HE4, ROMA, or a panel of markers
- Home collection charges
- Accreditation status of the laboratory
Insurance: outpatient diagnostic tests are often not covered unless your policy includes an OPD or diagnostics benefit. When CA-125 is done during an admission or as part of approved cancer treatment, it is more commonly reimbursed. Government schemes and hospital oncology packages may cover monitoring tests for enrolled patients. Confirm with your insurer or the hospital's billing desk before testing.
Myths and facts
| Myth | Fact |
|---|---|
| A raised CA-125 means cancer | Most raised CA-125 results in premenopausal women come from benign conditions such as endometriosis, fibroids, infection or menstruation. |
| A normal CA-125 means no ovarian cancer | Many early-stage and some specific subtypes of ovarian cancer do not raise CA-125. A normal result does not exclude disease. |
| Every woman should have an annual CA-125 | Screening asymptomatic average-risk women has not been shown to reduce ovarian cancer deaths and leads to unnecessary procedures. |
| CA-125 can replace a pelvic scan | CA-125 and ultrasound answer different questions. Neither substitutes for the other. |
| A small rise from 20 to 30 U/mL is dangerous | Both figures are commonly within the reference interval. Biological and assay variation is expected; interpretation depends on context and trend. |
| CA-125 detects cervical cancer | It does not. Cervical screening uses Pap smear and HPV testing. |
Frequently asked questions
Can the CA-125 test diagnose ovarian cancer?
No. The CA-125 test cannot diagnose ovarian cancer. It measures a protein that rises in many conditions affecting the abdominal and pelvic lining. Diagnosis needs imaging, specialist assessment and tissue examination under a microscope. CA-125 supports decision-making; it does not make the decision.
My CA-125 is slightly above the reference range. Should I panic?
No. Mild elevations are common, particularly before menopause, and often reflect menstruation, endometriosis, fibroids or recent infection. Your doctor will consider your symptoms, examination and usually a pelvic ultrasound, and may simply repeat the CA-125 test after a few weeks to see whether it settles.
Do I need to fast before the CA-125 test?
Fasting is not usually required for the CA-125 test alone. If it is clubbed with fasting glucose or a lipid profile, follow the fasting instructions for those tests. Requirements can differ between collection centres, so check the instruction given by your own laboratory.
Does the menstrual cycle affect CA-125?
Yes. CA-125 can rise during menstruation and in the early part of the cycle. If the result will influence an important decision, many clinicians prefer to sample outside the period. Tell the laboratory and your doctor where you are in your cycle when the sample is taken.
How is CA-125 different from HE4 and ROMA?
HE4 is a separate blood marker that is less likely to rise in endometriosis and fibroids, though it can rise in kidney disease. ROMA is a calculation combining CA-125, HE4 and menopausal status to estimate the risk that an ovarian mass is malignant. They complement CA-125 rather than replace it.
Should I get CA-125 as part of a routine health check?
Generally no, if you have no symptoms and no increased risk. In average-risk women, CA-125 produces many false alarms and has not been shown to reduce ovarian cancer deaths. Discuss with a doctor first; testing is most useful when there is a specific clinical question.
How often should CA-125 be repeated during cancer follow-up?
The interval depends on your cancer type, stage, treatment phase and your oncologist's plan. Some women are tested with each chemotherapy cycle; others at longer intervals during surveillance. Use the same laboratory where possible so the trend is comparable.
Can tuberculosis raise CA-125?
Yes, and this matters in India. Abdominal and pelvic tuberculosis can cause ascites, peritoneal thickening and a markedly raised CA-125, closely resembling advanced ovarian cancer on scans. Confirmation with fluid analysis, adenosine deaminase, culture or biopsy is important before treatment decisions are made.
How long does the whole process take?
The blood draw itself takes about five to ten minutes, and most people are in and out of the collection centre within 20 to 45 minutes. You can resume normal activity immediately. Ask your laboratory how soon the CA-125 report will be available, as this varies.
Sources
- National Institute for Health and Care Excellence (NICE), guidance on recognition and initial management of ovarian cancer
- Royal College of Obstetricians and Gynaecologists, guidance on the management of ovarian masses in premenopausal and postmenopausal women
- National Comprehensive Cancer Network (NCCN) guidelines, ovarian cancer including fallopian tube and primary peritoneal cancer
- US Preventive Services Task Force, recommendation statement on screening for ovarian cancer
- UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and PLCO screening trial publications
- Gynecologic Cancer InterGroup (GCIG) criteria for CA-125 response and progression
- Indian Council of Medical Research, National Cancer Registry Programme reports
